Skip to main content

Role of 18F-Fluciclovine and Prostate-Specific Membrane Antigen PET/CT in Guiding Management of Oligometastatic Prostate Cancer: AJR Expert Panel Narrative Review.

Publication ,  Journal Article
Savir-Baruch, B; Choyke, PL; Rowe, SP; Schuster, DM; Subramaniam, RM; Jadvar, H
Published in: AJR Am J Roentgenol
April 2021

Twenty-five years ago, oligometastatic disease was proposed as an intermediary clinical state of cancer with unique implications for therapies that may impact cancer evolution and patient outcome. Identification of limited metastases that are potentially amenable to targeted therapies fundamentally depends on the sensitivity of diagnostic tools, including new-generation imaging methods. For men with biochemical recurrence after definitive therapy of the primary prostate cancer, PET/CT using either the FDA-approved radiolabeled amino acid analogue 18F-fluciclovine or investigational radiolabeled agents targeting prostate-specific membrane antigen (PSMA) enables identification of early metastases at lower serum PSA levels than was previously feasible using conventional imaging. Evidence supports PSMA PET/CT as the most sensitive imaging modality available for identifying disease sites in oligometastatic prostate cancer. PSMA PET/CT will likely become the modality of choice after regulatory approval and will drive the development of trials of emerging metastasis-directed therapies such as stereotactic ablative body radiation and radioguided surgery. Indeed, numerous ongoing or planned clinical trials are studying advances in management of oligometastatic prostate cancer based on this heightened diagnostic capacity. In this rapidly evolving clinical environment, radiologists and nuclear medicine physicians will play major roles in facilitating clinical decision making and management of patients with oligometastatic prostate cancer.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

AJR Am J Roentgenol

DOI

EISSN

1546-3141

Publication Date

April 2021

Volume

216

Issue

4

Start / End Page

851 / 859

Location

United States

Related Subject Headings

  • Prostatic Neoplasms
  • Prostate-Specific Antigen
  • Positron Emission Tomography Computed Tomography
  • Nuclear Medicine & Medical Imaging
  • Male
  • Humans
  • Cyclobutanes
  • Carboxylic Acids
  • 3202 Clinical sciences
  • 1103 Clinical Sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Savir-Baruch, B., Choyke, P. L., Rowe, S. P., Schuster, D. M., Subramaniam, R. M., & Jadvar, H. (2021). Role of 18F-Fluciclovine and Prostate-Specific Membrane Antigen PET/CT in Guiding Management of Oligometastatic Prostate Cancer: AJR Expert Panel Narrative Review. AJR Am J Roentgenol, 216(4), 851–859. https://doi.org/10.2214/AJR.20.24711
Savir-Baruch, Bital, Peter L. Choyke, Steven P. Rowe, David M. Schuster, Rathan M. Subramaniam, and Hossein Jadvar. “Role of 18F-Fluciclovine and Prostate-Specific Membrane Antigen PET/CT in Guiding Management of Oligometastatic Prostate Cancer: AJR Expert Panel Narrative Review.AJR Am J Roentgenol 216, no. 4 (April 2021): 851–59. https://doi.org/10.2214/AJR.20.24711.
Savir-Baruch B, Choyke PL, Rowe SP, Schuster DM, Subramaniam RM, Jadvar H. Role of 18F-Fluciclovine and Prostate-Specific Membrane Antigen PET/CT in Guiding Management of Oligometastatic Prostate Cancer: AJR Expert Panel Narrative Review. AJR Am J Roentgenol. 2021 Apr;216(4):851–9.
Savir-Baruch, Bital, et al. “Role of 18F-Fluciclovine and Prostate-Specific Membrane Antigen PET/CT in Guiding Management of Oligometastatic Prostate Cancer: AJR Expert Panel Narrative Review.AJR Am J Roentgenol, vol. 216, no. 4, Apr. 2021, pp. 851–59. Pubmed, doi:10.2214/AJR.20.24711.
Savir-Baruch B, Choyke PL, Rowe SP, Schuster DM, Subramaniam RM, Jadvar H. Role of 18F-Fluciclovine and Prostate-Specific Membrane Antigen PET/CT in Guiding Management of Oligometastatic Prostate Cancer: AJR Expert Panel Narrative Review. AJR Am J Roentgenol. 2021 Apr;216(4):851–859.

Published In

AJR Am J Roentgenol

DOI

EISSN

1546-3141

Publication Date

April 2021

Volume

216

Issue

4

Start / End Page

851 / 859

Location

United States

Related Subject Headings

  • Prostatic Neoplasms
  • Prostate-Specific Antigen
  • Positron Emission Tomography Computed Tomography
  • Nuclear Medicine & Medical Imaging
  • Male
  • Humans
  • Cyclobutanes
  • Carboxylic Acids
  • 3202 Clinical sciences
  • 1103 Clinical Sciences